The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S.

Novo Nordisk stock fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its ...

COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for ...

COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk warned on Tuesday that full-year sales and operating profit would grow ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Since the US Food and Drug Administration (FDA) implemented a ban on ‘compounded’ versions of Wegovy on 22 May, new ...

Novo Nordisk, known for its obesity drug Wegovy, announced a reduction in its full-year sales and operating profit forecasts.

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

Current health news covers Roche's Alzheimer's drug research, UnitedHealth's leadership hopes, Nordic Capital's ...

New research has revealed that people taking weight loss drugs like Wegovy and Mounjaro are increasingly more likely to ...